Law360, New York (July 20, 2009) -- Solvay Pharmaceuticals Inc. and Watson Pharmaceuticals Inc. are aiming to throw out the Federal Trade Commission’s suit that alleges patent settlements over the testosterone supplement AndroGel restrained competition, arguing that the settlements are legal under an appeals court’s precedent.
The drug firms lodged a motion in the U.S. District Court for the Northern District of Georgia on Monday seeking to dismiss the FTC’s complaint because, they said, it failed...
